Genelux Corporation (GNLX) Financial Statements (2025 and earlier)

Company Profile

Business Address 2625 TOWNSGATE ROAD, SUITE 230
WESTLAKE VILLAGE, CA 91361
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23,191
Cash and cash equivalents9,418
Short-term investments13,773
Other undisclosed cash, cash equivalents, and short-term investments 
Deferred costs 303
Other undisclosed current assets709
Total current assets:24,203
Noncurrent Assets
Operating lease, right-of-use asset2,428
Property, plant and equipment1,170
Long-term investments and receivables 
Long-term investments 
Other noncurrent assets92
Total noncurrent assets:3,690
TOTAL ASSETS:27,893
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,784
Accrued liabilities2,117
Other undisclosed accounts payable and accrued liabilities1,667
Debt 900
Other undisclosed current liabilities1,870
Total current liabilities:6,554
Noncurrent Liabilities
Liabilities, other than long-term debt1,866
Operating lease, liability1,866
Total noncurrent liabilities:1,866
Total liabilities:8,420
Equity
Equity, attributable to parent19,473
Common stock27
Treasury stock, value(433)
Additional paid in capital241,389
Accumulated other comprehensive income14
Accumulated deficit(221,524)
Total equity:19,473
TOTAL LIABILITIES AND EQUITY:27,893

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
Revenues170
Gross profit:170
Operating expenses(24,335)
Operating loss:(24,165)
Nonoperating income (expense)(4,132)
Investment income, nonoperating244
Other nonoperating expense (3,152)
Interest and debt expense (402)
Loss from continuing operations before equity method investments, income taxes:(28,699)
Other undisclosed loss from continuing operations before income taxes 
Net loss:(28,699)
Other undisclosed net income attributable to parent402
Net loss available to common stockholders, diluted:(28,297)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
Net loss:(28,699)
Comprehensive loss:(28,699)
Other undisclosed comprehensive income, net of tax, attributable to parent414
Comprehensive loss, net of tax, attributable to parent:(28,285)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: